MAP4Ks inhibition promotes retinal neuron regeneration from Müller glia in adult mice

Houjian Zhang1,2,3, Yuli Guo1,2,3, Yaqiong Yang1

  • 1Department of Ophthalmology, Xiang'an Hospital of Xiamen University; Fujian Provincial Key Laboratory of Ophthalmology and Visual Science; Fujian Engineering and Research Center of Eye Regenerative Medicine; Eye Institute of Xiamen University; School of Medicine, Xiamen University, Xiamen, Fujian, 361005, China.

PubMed

Insights

In adult mammals, MAP4K kinases inhibit Müller glia (MG) reprogramming. Inhibiting these kinases, particularly MAP4K4/6/7, restores MG plasticity and promotes retinal neuron generation, offering a new therapeutic strategy for retinal regeneration.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Ophthalmology

Background:

  • Mammalian Müller glia (MG) have limited regenerative potential.
  • The intrinsic ability of MG to transdifferentiate into neurons without genetic modification is largely unexplored.

Purpose of the Study:

  • To investigate the role of MAP4K kinases in regulating MG reprogramming capacity.
  • To explore the potential of inhibiting MAP4K kinases for inducing retinal regeneration.

Main Methods:

  • Utilized small molecule inhibitors targeting MAP4K4/6/7 in mouse models.
  • Assessed Müller glia proliferation, progenitor cell state, and transdifferentiation post-NMDA induced retinal damage.
  • Investigated the role of YAP in MG plasticity using YAP knockout models.

Main Results:

  • MAP4K4, MAP4K6, and MAP4K7 were identified as repressors of YAP activity in mammalian MG, limiting their reprogramming.
  • Inhibition of MAP4K4/6/7 restored MG proliferation and induced a retinal progenitor cell (RPC)-like state after retinal injury.
  • YAP knockout mice showed a loss of this MG plasticity.
  • MG spontaneously transdifferentiated into amacrine and retinal ganglion cells (RGCs) after inhibitor withdrawal.

Conclusions:

  • MAP4K kinases, via YAP-dependent mechanisms, inhibit the reprogramming capacity of MG in adult mammals.
  • Targeting MAP4Ks offers a novel pharmaceutical approach for inducing retinal regeneration in vivo.

Related Concept Videos